PDF(Pubmed)
Abstract：
Breast cancer poses a global health challenge, yet the influence of ethnicity on the tumor microenvironment (TME) remains understudied. In this investigation, we examined immune cell infiltration in 230 breast cancer samples, emphasizing diverse ethnic populations. Leveraging tissue microarrays (TMAs) and core samples, we applied multiplex immunofluorescence (mIF) to dissect immune cell subtypes across TME regions. Our analysis revealed distinct immune cell distribution patterns, particularly enriched in aggressive molecular subtypes triple-negative and HER2-positive tumors. We observed significant correlations between immune cell abundance and key clinicopathological parameters, including tumor size, lymph node involvement, and patient overall survival. Notably, immune cell location within different TME regions showed varying correlations with clinicopathologic parameters. Additionally, ethnicities exhibited diverse distributions of cells, with certain ethnicities showing higher abundance compared to others. In TMA samples, patients of Chinese and Caribbean origin displayed significantly lower numbers of B cells, TAMs, and FOXP3-positive cells. These findings highlight the intricate interplay between immune cells and breast cancer progression, with implications for personalized treatment strategies. Moving forward, integrating advanced imaging techniques, and exploring immune cell heterogeneity in diverse ethnic cohorts can uncover novel immune signatures and guide tailored immunotherapeutic interventions, ultimately improving breast cancer management.
摘要：
乳腺癌构成了全球健康挑战，然而，种族对肿瘤微环境（TME）的影响仍未得到充分研究。在这次调查中,我们检查了230份乳腺癌样本中的免疫细胞浸润，强调不同的民族。利用组织微阵列（TMA）和核心样品，我们应用多重免疫荧光（mIF）来解剖跨TME区域的免疫细胞亚型。我们的分析揭示了不同的免疫细胞分布模式，特别是富含侵袭性分子亚型三阴性和HER2阳性肿瘤。我们观察到免疫细胞丰度与关键临床病理参数之间存在显着相关性，包括肿瘤大小,淋巴结受累,和患者总体生存率。值得注意的是,不同TME区域的免疫细胞位置与临床病理参数有不同的相关性.此外,种族表现出不同的细胞分布，与其他种族相比，某些种族表现出更高的丰度。在TMA样品中,中国和加勒比裔患者的B细胞数量明显减少，TAM,和FOXP3阳性细胞。这些发现强调了免疫细胞和乳腺癌进展之间复杂的相互作用，对个性化治疗策略的影响。往前走,集成先进的成像技术，探索不同种族群体的免疫细胞异质性可以发现新的免疫特征，并指导量身定制的免疫治疗干预措施，最终改善乳腺癌的管理。
